Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting

Figures & data

Table 1. Number of reported hepatitis A infections for a 10-year period and number of children aged 1 for the observation period.

Year	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	Average number
Registered cases	4753	2155	3990	5225	7266	2800	908	1064	2350	5588	5023	3738
One-year old children cohort	68180	66499	67359	69886	71075	73978	75349	77712	80956	75513	70846	72,486

Table 2. Input model parameters.

Cost of treatment of registered acute hepatitis A infection
Parameters		Source
Cohort	Registered patients with viral hepatitis A for the period 2002–2012	National Center of Public Health
Hospitalization cost	Increases from 600 BGN to 1000 BGN	National Framework Contract
Ambulatory pharmacotherapy (hepatoprotectors)	Calculated for three-month period for each of the years in the period observed in current prices	[29]
Biochemical monitoring test	10 BGN	National Framework Contract
Assumed costs for vaccination at the National Health Insurance Fund (NHIF) prices
Cohort	Number of children at the age of 1 for each of the years in the period 2002–2012	National Statistical Institute
Vaccine–immunization plan (1 + 1)	Inactivated HAV vaccine – 56.64 BGN	Positive Drug List (PDL)

Figure 1. Difference between the total treatment costs (in BGN) and vaccination costs per year.

Figure 2. Aggregate net benefit for the period 2002–2012 (in BGN).

Figure 3. Impact of the variation of number of patients with HAV infection (A) and the variation of cost of HAV vaccine (B) on the net benefit.

Figure 4. Tornado diagram on the impact of uncertain input parameters in the model on the net benefit.

Savova A. Regulatory characteristics and utilization of herbal medicinal products [dissertation]. Sofia (Bulgaria): Medical University of Sofia, Faculty of Pharmacy; 2006.

 Google Scholar